Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CDIO NASDAQ:CVKD NASDAQ:ENLV NASDAQ:FBLG On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCDIOCardio Diagnostics$3.87+2.2%$3.91$3.22▼$53.10$6.72M2.9635,912 shs6,837 shsCVKDCadrenal Therapeutics$12.96-2.5%$11.81$6.89▼$22.90$26.53M0.9334,093 shs15,105 shsENLVEnlivex Therapeutics$1.05+1.0%$1.26$0.81▼$2.10$24.83M0.81.28 million shs205,727 shsFBLGFibroBiologics$0.59-4.9%$0.63$0.53▼$4.41$24.72M-0.74459,646 shs342,935 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCDIOCardio Diagnostics0.00%+5.27%-6.43%-5.28%-65.80%CVKDCadrenal Therapeutics0.00%+3.85%+24.38%-2.85%+77.29%ENLVEnlivex Therapeutics0.00%0.00%-29.53%+8.99%-16.67%FBLGFibroBiologics0.00%+0.25%-7.36%-17.48%-63.12%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCDIOCardio Diagnostics1.0961 of 5 stars0.03.00.00.03.31.70.6CVKDCadrenal Therapeutics2.7761 of 5 stars3.53.00.00.02.12.50.6ENLVEnlivex Therapeutics3.142 of 5 stars3.55.00.00.03.10.80.6FBLGFibroBiologics2.5805 of 5 stars3.63.00.00.02.70.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCDIOCardio Diagnostics 0.00N/AN/AN/ACVKDCadrenal Therapeutics 3.00Buy$32.00146.91% UpsideENLVEnlivex Therapeutics 3.00Buy$10.00852.38% UpsideFBLGFibroBiologics 3.20Buy$13.002,103.02% UpsideCurrent Analyst Ratings BreakdownLatest CDIO, CVKD, ENLV, and FBLG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/18/2025ENLVEnlivex TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.008/5/2025FBLGFibroBiologicsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $12.008/4/2025FBLGFibroBiologicsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.007/29/2025ENLVEnlivex TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.007/29/2025FBLGFibroBiologicsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.007/22/2025ENLVEnlivex TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.007/9/2025FBLGFibroBiologicsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.006/17/2025FBLGFibroBiologicsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00(Data available from 8/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCDIOCardio Diagnostics$40K170.46N/AN/A$5.52 per share0.70CVKDCadrenal TherapeuticsN/AN/AN/AN/A$2.10 per shareN/AENLVEnlivex TherapeuticsN/AN/AN/AN/A$1.00 per shareN/AFBLGFibroBiologicsN/AN/AN/AN/A$0.02 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCDIOCardio Diagnostics-$8.38MN/A0.00∞N/A-30,465.10%-72.78%-66.17%11/12/2025 (Estimated)CVKDCadrenal Therapeutics-$10.65M-$8.88N/AN/AN/AN/A-265.37%-196.38%11/6/2025 (Estimated)ENLVEnlivex Therapeutics-$15.01M-$0.66N/AN/AN/AN/A-57.67%-50.52%N/AFBLGFibroBiologics-$11.16M-$0.36N/AN/AN/AN/A-710.25%-118.02%11/11/2025 (Estimated)Latest CDIO, CVKD, ENLV, and FBLG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025CDIOCardio Diagnostics-$1.80-$0.97+$0.83-$0.97$0.08 million$0.01 million8/11/2025Q2 2025CVKDCadrenal Therapeutics-$1.60-$1.87-$0.27-$1.87N/AN/A7/31/2025Q1 2025FBLGFibroBiologics-$0.11-$0.12-$0.01-$0.12N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCDIOCardio DiagnosticsN/AN/AN/AN/AN/ACVKDCadrenal TherapeuticsN/AN/AN/AN/AN/AENLVEnlivex TherapeuticsN/AN/AN/AN/AN/AFBLGFibroBiologicsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCDIOCardio DiagnosticsN/A23.5223.52CVKDCadrenal TherapeuticsN/A3.553.55ENLVEnlivex TherapeuticsN/A7.207.20FBLGFibroBiologicsN/A0.930.93Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCDIOCardio Diagnostics8.06%CVKDCadrenal Therapeutics7.92%ENLVEnlivex Therapeutics1.02%FBLGFibroBiologicsN/AInsider OwnershipCompanyInsider OwnershipCDIOCardio Diagnostics22.30%CVKDCadrenal Therapeutics26.09%ENLVEnlivex Therapeutics12.28%FBLGFibroBiologics20.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCDIOCardio Diagnostics11.76 million1.37 millionNot OptionableCVKDCadrenal Therapeutics42.05 million1.51 millionNot OptionableENLVEnlivex Therapeutics7023.65 million20.75 millionOptionableFBLGFibroBiologics1041.89 million33.51 millionN/ACDIO, CVKD, ENLV, and FBLG HeadlinesRecent News About These CompaniesFibroBiologics to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceAugust 27, 2025 | globenewswire.comFBLG: Closes Third Tranche of $5M…August 5, 2025 | msn.comFibroBiologics, Inc.: FibroBiologics Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 1, 2025 | finanznachrichten.deFibroBiologics Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateJuly 31, 2025 | globenewswire.comFibroBiologics Files Patent for Methods of Generating Multipotent Cells from Donor Tissue for Clinical ApplicationsJuly 28, 2025 | globenewswire.comBrag House and FibroBiologics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVJuly 11, 2025 | usatoday.comFibroBiologics to Present at the Advanced Wound Care Summit USAJuly 11, 2025 | globenewswire.comFibroBiologics Confirms Ability to Manufacture CybroCell™ for ...July 10, 2025 | finance.yahoo.comFibrobiologics Confirms Ability to Manufacture Cybrocell for Degenerative Disc Disease and Cartilage Repair Programs from Existing Cywc628 Master Cell BankJuly 9, 2025 | marketscreener.comMFibroBiologics Confirms Ability to Manufacture CybroCell™ for Degenerative Disc Disease and Cartilage Repair Programs from Existing CYWC628 Master Cell BankJuly 9, 2025 | globenewswire.comFibroBiologics’ to Present at Exclusive Live Investor Webinar and Q&A Session on July 10July 7, 2025 | finance.yahoo.comFibroBiologics' to Present at Exclusive Live Investor Webinar and Q&A Session on July 10July 7, 2025 | globenewswire.comFibroBiologics, Inc. (FBLG) - Yahoo FinanceJune 24, 2025 | finance.yahoo.comFibroBiologics to Present Company Update and Research Advances at BIO International Convention 2025June 17, 2025 | nasdaq.comFibroBiologics Secures $5M in Equity Purchase AgreementJune 16, 2025 | tipranks.comFibroBiologics Closes Third $5 Million Tranche of $25 Million FinancingJune 16, 2025 | globenewswire.comFibroBiologics to Present at the BIO International Convention 2025June 16, 2025 | globenewswire.comFibroBiologics, Inc. Holds Annual Stockholders MeetingJune 13, 2025 | tipranks.comFibroBiologics Appoints Jason D. Davis as CFOJune 9, 2025 | tipranks.comFibrobiologics, Inc.: FibroBiologics Appoints Jason D. Davis, CPA, as Chief Financial OfficerJune 9, 2025 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCDIO, CVKD, ENLV, and FBLG Company DescriptionsCardio Diagnostics NASDAQ:CDIO$3.87 +0.08 (+2.22%) Closing price 08/29/2025 03:50 PM EasternExtended Trading$3.80 -0.07 (-1.91%) As of 08/29/2025 07:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.Cadrenal Therapeutics NASDAQ:CVKD$12.96 -0.33 (-2.48%) Closing price 08/29/2025 03:59 PM EasternExtended Trading$12.86 -0.10 (-0.73%) As of 08/29/2025 06:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.Enlivex Therapeutics NASDAQ:ENLV$1.05 +0.01 (+0.96%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$1.06 +0.01 (+0.95%) As of 08/29/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.FibroBiologics NASDAQ:FBLG$0.59 -0.03 (-4.85%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$0.60 +0.01 (+2.19%) As of 08/29/2025 07:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.FibroBiologics, Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc. was incorporated in 2021 and is based in Houston, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/25 - 08/29 Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Tencent Music Stock Outshines Spotify as China’s Music Giant Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? DICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
